Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer

Yu Zhang, Fei Wang, Haoran Sun, Yakai Huang, Jianpeng Gao, Hua HuangResearch 2020 · DOI

Abstract

Abstract Background: Apatinib, an antiangiogenic drug, has showed beneficial effects only in a fraction of advanced gastric cancer (GC) patients. Given the recent success of immunotherapies, combination of apatinib with immune checkpoint inhibitor may provide sustained and potent antitumor responses. Methods: Immunocompetent mice with subcutaneous MFC tumors grown were given combination of apatinib and anti-PD-L1 antibody therapy. GC tissues from patients undergoing curative resection in China were collected, and the density of HEVs, MSI status and tumor-infiltrated lymphocytes were analyzed by immunohistochemical staining. Results: Combined apatinib and PD-L1 blockade therapy synergistically delayed tumor growth and increased survival in MFC-bearing immunocompetent mice. The combination therapy promoted antitumor immunity by increasing the ratio of CD8 + cytotoxic T cells to Foxp3 + Treg cells, the accumulation of CD20 + B cells and the Th1/Th2 cytokine ratio (IFN-γ/IL-10). The combination therapy induced the formation of HEVs through activation of LTβR signaling mediated by DCs, thus promoting CD8 + cytotoxic T cell and CD20 + B cell infiltration in tumors. In clinical GC samples, the density of HEVs positively correlated with the intratumoral infiltration of CD8 + cytotoxic T cells and CD20 + B cells. MSI-high GC showed a higher density of HEVs, CD8 + cytotoxic T cells and CD20 + B cells than MSS/MSI-low GC. GC patients with high densities of HEVs, CD8 + cytotoxic T cells and CD20 + B cells had an improved prognosis with superior overall survival. Conclusions: Combining apatinib with PD-L1 blockade treatment synergistically enhances antitumor immune responses and promotes HEV formation in GC.
BibTeX
@inproceedings{zhang2020apatinib,
  author = {Yu Zhang and Fei Wang and Haoran Sun and Yakai Huang and Jianpeng Gao and Hua Huang},
  title = {{Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-95102/v1},
}

Loading related content...

Figure